Vigilant Hikma bounces from Arab Spring with $200m on hand for acquisitions

Following the political and social upheaval of the Arab Spring, Hikma Pharmaceuticals is poised for expansion into markets that are now much more receptive than before. Said Darwazah, CEO of the Jordan-based speciality pharma group, told Scrip that while the political disruptions in the Middle East only cut a company-estimated $20 million from sales revenue in 2011, the situation has transformed some markets into an opportunity for accelerated growth.

Following the political and social upheaval of the Arab Spring, Hikma Pharmaceuticals is poised for expansion into markets that are now much more receptive than before. Said Darwazah, CEO of the Jordan-based speciality pharma group, told Scrip that while the political disruptions in the Middle East only cut a company-estimated $20 million from sales revenue in 2011, the situation has transformed some markets into an opportunity for accelerated growth.

"Governments are responding to the Arab Spring by increasing spending on healthcare," observed Mr Darwazah, adding that Hikma was well...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

Test

Sponsored by :

Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical

As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.